Ranbaxy, Dr Reddy’s and other Indian drug makers, which earn a third of their earnings from selling products in the US, need higher drug approvals from the Food and Drug Administration (FDA) of that country in the next financial year to maintain 20 per cent sales growth.
The requirement comes at a time when the US, the world’s biggest drug market, is facing a slowdown and one of India’s leading drug makers, Ranbaxy, is being investigated Read the rest of this entry »

ScienceDaily (Jan. 22, 2009)
— Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth. Their findings, recently reported online at the Proceedings of the National Academy of Sciences Early Edition, suggest that a subgroup of cancer patients might particularly benefit from these drugs.
The anthracycline class of chemotherapeutics — doxorubicin Read the rest of this entry »

(Adds analyst reaction beginning in seventh paragraph and updated stock
price.)
Eli Lilly & Co.
(LLY) expects to swing to a profit in
2009 from an anticipated loss in 2008 but sees sales growth slowing due to less
favorable currency exchange rates as well as generic competition for one of its
cancer drugs.
$6.5 billion
acquisition of ImClone Systems would result in a large charge for the fourth
quarter, causing the full-year net loss. The Read the rest of this entry »

Glaxo CEO Sees ‘Sustainable Growth’ From Deals, Drugs (Update1)
Jan. 9 (Bloomberg) –
, Europe’s largest
drugmaker, will boost its reliance on acquisitions and licensing
deals to bring new medicines to the market, Chief Executive
Officer Andrew Witty said in an interview.
The London-based company has 30 drugs in the final stage of
testing needed before approval and plans to release about five
new products a year, Witty, 44, said yesterday. Read the rest of this entry »

Glaxo CEO Sees ‘Sustainable Growth’ From Deals, Drugs (Update2)
Jan. 9 (Bloomberg) –
, Europe’s largest
drugmaker, will boost its reliance on acquisitions and licensing
deals to bring new medicines to the market, Chief Executive
Officer Andrew Witty said in an interview.
The London-based company has 30 drugs in the final stage of
testing needed before approval and plans to release about five
new products a year, Witty, 44, said yesterday. Read the rest of this entry »

During its regular meeting Wednesday night, the Otero County Commission discussed plans for a growth study to prepare for the population explosion anticipated at area military bases.
The discussion focused on a memorandum of understanding between Otero County, DoГ±a Ana County, the city of Alamogordo and the city of Las Cruces. The MOU is the first step in working with the Department of Defense’s Office of Economic Adjustment to ease the growing Read the rest of this entry »

Table 1
IMS Health
GAAP Income Statement
Three
Months Ended September 30
(unaudited, in millions
except per share)
2008 2007 % Fav Non-GAAP
GAAP GAAP (Unfav) Constant $
Read the rest of this entry »

The global outlook series on Pharmaceuticals provides a collection of
statistical anecdotes, market briefs, and concise summaries of research
findings. The report provides a bird’s eye view of the pharmaceutical
industry, and highlights global trends impacting the marketplace, such
as, patent expiry of blockbuster global drugs, rising demand for old age
related medications and cardiovascular drugs, and the rise Read the rest of this entry »

®
(NYSE: PAR), the leading global provider of
, announced
today that leading women’s online health portal
has deployed
3PAR Utility Storage for affordable, scalable, and highly intelligent
storage as part of an enhanced utility computing environment. With 3PAR,
LifeScript’s Web 2.0 portal and email processing engine now supports three
billion transactions per month for a third less cost than their previous
storage environment. LifeScript’s new Read the rest of this entry »

That’s the ironic truth facing epidemiologists around the country.
The popularity of cellular telephones, an increasingly mobile population, rising expenses, flat budgets and new insights into ways people can answer a question differently depending on how it’s asked — all are conspiring to make health surveys more difficult.
In public health, pretty much everything depends on good data. Researchers and policymakers can’t identify a problem, figure Read the rest of this entry »